|
|
 |
|
Viewing report
|
|
|
|
2010 Alzheimer's Disease Drug Development Special Report: Insights on Emerging Therapies from Payer and Provider Prospectives
Reimbursement Intelligence, Jan 2011, Pages: 250
In the Alzheimer’s Disease Drug Development Special Report, the author in collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) will issue a landmark resource for manufacturers with Alzheimer’s Disease pipeline or inline products.
- Understand current Alzheimer’s Disease market landscape and unmet treatment need
- Response to clinical and economic endpoints of pipeline therapies
-- Passive immunotherapies
-- Y-secretase inhibitors
-- IVIG
-- Passive/active vaccines
-- Tau protein therapies
-- Cognitive enhancers
- Role of biomarkers and diagnostics in identification and management of Alzheimer’s Disease and patient care
- Payer evidence requirements to demonstrate medical cost offsets, cost effectiveness, and health outcomes
- Understand how providers will utilize emerging therapies in clinical practice
Why Purchase the Reimbursement iQ 2010 Alzheimer’s Disease Drug Development Special Report?
Build an effective health outcomes research plan
Design reimbursement plan based on physician and payer perspectives
Understand project formulary placement, reimbursement, and utilization restriction
Gain intelligence on pricing and revenue forecasting
Obtain physician feedback on patient selection, use of new therapies, and clinical expectations
In collaboration with the Alzheimer's Drug Discovery Foundation (ADDF), RI has created this resource to gain critical intelligence on:
- How to respond to clinical and economic endpoints of in-line and pipeline therapies
- Demonstrating medical cost offsets, cost effectiveness, and health outcomes by obtaining payer evidence requirements
- How providers will utilize emerging therapies in clinical practice
Pharmaceutical and device manufacturers who purchase the report can use the findings to:
- Build an effective health outcomes and clinical plan
- Design a reimbursement plan based on physician and payer perspectives
- Obtain physician feedback on patient selection, use of new therapies, and clinical expectations
Products Mentioned:
- Passive immunotherapies
- Y-secretase inhibitors
- IVIG
- passive/active vaccines
- Tau protein therapies and cognitive enhancers
|
|
|
|
